Specialty Pharma Journal Specialty, Precision & Technology
INDIANAPOLIS and LAUSANNE, Switzerland, Dec. 12, 2018 /PRNewswire/ — Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development …
Tag Archives: Alzheimer’s disease
December, 2018
November, 2018
-
15 November
Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease
CAMBRIDGE, England and NORTH CHICAGO, Ill.–(BUSINESS WIRE)–Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”)(NYSE: ABBV), a research-based global biopharmaceutical company, today announced a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease …
-
1 November
Sanofi and Denali Therapeutics Partner to Develop Treatments for Neurological and Inflammatory Diseases
PARIS, France – November 1, 2018 – Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules (DNL747 and DNL758) target a critical signaling protein known as the receptor-interacting serine/threonine-protein …
October, 2018
-
26 October
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab
CAMBRIDGE, Mass., Oct. 26, 2018 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that Biogen presented results at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension (LTE) of …
-
25 October
Biogen and Eisai Present Additional Data from Phase 2 Trial of Investigational Treatment for Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced that Eisai presented the latest data from the Phase II clinical study (Study 201) of BAN2401, …
August, 2018
-
29 August
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced results from a recent analysis of the ongoing long-term extension (LTE) Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and …
-
6 August
Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Key Driver of Alzheimer’s Disease
FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the discovery of an endogenous substance in human brain that inhibits the formation of neurotoxic beta amyloid (Aβ) oligomers, which are key drivers of AD …
-
3 August
Newly Characterized Molecule Offers Possibilities for Novel Alzheimer’s Treatments
Alzheimer’s disease is an increasingly prevalent, neurodegenerative condition that erodes memory and other cognitive functions. Treatments for this complex disease have been elusive, although researchers have previously uncovered its main biological features: amyloid-beta plaques and tau tangles. A study by researchers from Brigham and Women’s Hospital (BWH), recently published in Acta …
July, 2018
-
25 July
Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease and Planned Confirmatory Clinical Trial with ALZ-801
FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurological and psychiatric disorders, today announced the upcoming presentation of data at the Alzheimer’s Association International Conference (AAIC) in Chicago on Wednesday, July 25th, 2018. The presentation at the …
-
17 July
FDA Grants Fast Track Designation to Tonix Pharmaceuticals’ Investigational Treatment for Agitation in Alzheimer’s Disease
NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational new drug, TNX-102 SL, for the treatment of agitation in Alzheimer’s disease. The same drug, TNX-102 SL, or …